Currently, United Therapeutics Corp [UTHR] is trading at $236.97, up 3.12%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The UTHR shares have gain 4.26% over the last week, with a monthly amount glided 11.38%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 5, March 2024, United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024. In a post published today on Yahoo Finance, United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.
From an analyst’s perspective:
United Therapeutics Corp [NASDAQ: UTHR] stock has seen the most recent analyst activity on February 12, 2024, when Goldman upgraded its rating to a Neutral and also boosted its price target to $215 from $213. Previously, Leerink Partners started tracking the stock with Outperform rating on February 05, 2024, and set its price target to $330. On December 08, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $309 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $320 on December 06, 2022. Goldman initiated its recommendation with a Sell and recommended $230 as its price target on December 05, 2022. Morgan Stanley started tracking with a Overweight rating for this stock on October 11, 2022, and assigned it a price target of $288. In a note dated September 20, 2022, BofA Securities reiterated an Underperform rating on this stock.
This stock has fluctuated between a low of $204.44 and a high of $261.54 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $268.75 within the next 12 months. United Therapeutics Corp [NASDAQ: UTHR] shares were valued at $236.97 at the most recent close of the market. An investor can expect a potential return of 13.41% based on the average UTHR price forecast.
Analyzing the UTHR fundamentals
Trailing Twelve Months sales for United Therapeutics Corp [NASDAQ:UTHR] were 2.33B which represents 25.07% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.51%, Pretax Profit Margin comes in at 0.55%, and Net Profit Margin reading is 0.42%. To continue investigating profitability, this company’s Return on Assets is posted at 0.14, Equity is 0.18 and Total Capital is 0.19. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 231.03 points at the first support level, and at 225.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 241.88, and for the 2nd resistance point, it is at 246.79.
United Therapeutics Corp [UTHR] reported earnings per share of $4.36 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $4.19/share, meaning a difference of $0.17 and a surprise factor of 4.10%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $5.38 per share as compared to estimates of $5.04 per share, a difference of $0.34 representing a surprise of 6.70%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for United Therapeutics Corp [NASDAQ:UTHR] is 4.41. Further, the Quick Ratio stands at 4.28, while the Cash Ratio is 1.5. Considering the valuation of this stock, the price to sales ratio is 4.79, the price to book ratio is 1.86 and price to earnings (TTM) ratio is 11.95.
Transactions by insiders
Recent insider trading involved PATUSKY CHRISTOPHER, Director, that happened on Feb 23 ’24 when 1680.0 shares were sold. EVP & GENERAL COUNSEL, MAHON PAUL A completed a deal on Feb 15 ’24 to sell 6000.0 shares. Meanwhile, EVP & GENERAL COUNSEL MAHON PAUL A sold 6000.0 shares on Feb 01 ’24.
